市場調查報告書
商品編碼
1355795
非小細胞肺癌的免疫療法市場:KOL的洞察Non-Small Cell Lung Cancer - Immunotherapies - KOL Insight |
本報告提供全球非小細胞肺癌(NSCLC)的免疫療法市場相關調查,提供市場概要,以及已通過核准治療方法,開發平台趨勢,未來預測等資訊。
How do KOLs interpret data from Checkmate-816, and how does this now inform the treatment of patients with early-stage resectable NSCLC without EGFR or ALK genomic alterations? Why do oncologists say the KEYNOTE-671 findings for Merck & Co.'s Keytruda will likely impact NSCLC treatment practice? How do experts assess the potential to re-challenge with IO-based therapy? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to KOL Bulletins via the Attachments area.